{
}
Merck's cardiovascular drug Winrevair has shown promising results in the ZENITH trial, significantly improving survival and reducing the need for invasive care in patients with severe lung hypertension compared to those on standard therapy. The trial was halted early due to its clear efficacy, potentially expanding the drug's use and driving sales, which are projected to reach $5 billion annually. Winrevair, approved earlier this year, treats pulmonary arterial hypertension and has already generated $219 million in sales through September 30.
Merck & Co. has acquired worldwide rights to LaNova Medicines' cancer therapy LM-299 for $588 million, a bispecific immunotherapy targeting PD-1 and VEGF, currently in Phase 1 testing. This move comes as a response to increasing competition, particularly after ivonescimab outperformed Keytruda in a lung cancer trial. The deal could yield LaNova up to $2.7 billion based on development milestones, highlighting Merck's strategy to bolster its pipeline ahead of Keytruda's patent expiration in 2028.
Umer Raffat
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Merck's Winrevair shows promise in severe lung hypertension treatment trial
01:00 25.11.2024
merck invests in new cancer immunotherapy to counter keytruda competition
United States Dollar
LaNova Medicines
Merck & Co., Inc.
Summit Therapeutics plc
Biotheus
Eisai Co., Ltd.
BioNTech SE
Akeso, Inc.
USA
CHN
Umer Raffat
Dean Li
Show more
01:00 14.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Startups & Entrepreneurship
Market Analysis and Predictions
Banking Regulations
CEO Changes
Industry Mergers & Acquisitions
Government Economic Policies
Government Policies
Inflation and Monetary Impact
Central Bank Actions
GDP Growth & Recession Forecasts
Financial Scams and Security
Hedge Funds & Private Equity
Consumer Protection Regulations
Countries:
Companies:
JPMorgan Chase & Co.
Barclays PLC
Apple Inc.
Tesla, Inc.
Berkshire Hathaway Inc.
The Goldman Sachs Group, Inc.
Banco Santander, S.A.
Microsoft Corporation
Morgan Stanley
Wells Fargo & Company
Citigroup Inc.
Commerzbank AG
Amazon.com, Inc.
SpaceXCoin USD
Deutsche Bank Money Market PP
NVIDIA Corporation
Lloyds Banking Group plc
Bank of America Corporation
Royal Bank of Canada
UBS Group AG
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Chinese Yuan
South Korean Won
New Taiwan Dollar
Canadian Dollar
United Arab Emirates Dirham
Vietnamese Đồng
Danish Krone
Indonesian Rupiah
Russian Ruble
Singapore Dollar
Chilean Peso
Egyptian Pound
Cambodian Riel
Israeli New Shekel
People: